Atezolizumab Approved for Metastatic Nonsquamous NSCLC

After granting Priority Review, the FDA has approved atezolizumab (Tecentriq®, Genentech, Inc.), a monoclonal antibody, to be used in combination with carboplatin/paclitaxel/bevacizumab (CPB) for patients with previously untreated metastatic nonsquamous, non-small cell lung cancer (NSCLC) without EGFR or ALK tumor mutations. The approval was based on the open-label, three-arm IMpower150 trial (NCT02366143), for which patients were randomized 1:1:1 to a regimen of atezolizumab plus CPB, a regimen...
Continue reading

Novel Management Strategies for Immune-Related Pruritus: An Interview With Shawn Kwatra, MD

Immunotherapies such as PD-1 inhibitors have improved survival for many patients with cancer. However, these therapies are associated with adverse events that, if not properly managed, impair quality of life and may lead to treatment interruptions or discontinuation. Pruritus is one of the most common immune-related adverse events, and while many cases may be managed with conventional therapy, some patients do not respond. Shawn Kwatra, MD and colleagues reported on a case of an 88-year-old woman receiving pembrolizumab, a PD-1 inhibitor, for metastatic lung adenocarcinoma who developed severe pruritus refractory to standard treatment. Dr. Kwatra and colleagues found that intravenous naloxone, an opioid antagonist, resulted in a reduction in pruritus severity from 10 to 1 (on a scale of 0 to 10) within 1 hour. i3 Health spoke with Dr. Kwatra, Assistant Professor of Dermatology at Johns Hopkins University School of Medicine, about his findings and the challenges, potential advances, and role of multidisciplinary care in the management of dermatologic immune-related adverse events.

Continue reading

Lorlatinib Approved for ALK-Positive Metastatic NSCLC

Lorlatinib ( L orbrena ® , Pfizer, Inc.) is approved as second- or third-line treatment for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease. FDA approval was granted based on a non-randomized, dose-ranging and activity-estimati...
Continue reading

FDA Approves Pembrolizumab Combo for Treatment of Non-Small Cell Lung Cancer

The PD-1 inhibitor pembrolizumab (Keytruda®, Merck & Co., Inc.) in combination with carboplatin and either paclitaxel or nab-paclitaxel has received FDA approval as first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC). Pembrolizumab was previously granted approval in August for the first-line treatment of patients with metastatic non-squamous NSCLC without EGFR or ALK genomic tumor aberrations. The expanded indication marks the first time an anti–PD-1 regimen has be...
Continue reading

Lung Cancer Risk From Common Blood Pressure Medications

Angiotensin converting enzyme (ACE) inhibitors are effective at controlling high blood pressure, but according to a recent study, they also increase the risk for lung cancer. A research team headed by Laurent Azoulay, PhD, Senior Investigator at the Lady Davis Institute and Associate Professor of Oncology at McGill University in Montreal, Canada, analyzed data from the UK Clinical Practice Research Datalink (CPRD) on 992,061 British patients newly treated with antihypertensive drugs between Janu...
Continue reading
© Copyright 2018 i3 Health. All rights reserved.